Updated: 3/23/2011 4:30 p.m.
Elizabeth Taylor made the hearts race for decades, but it was her own heart that failed in the end.
The 79-year-old actress died today from congestive heart failure, a condition that she fought for almost eight years.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Updated: 3/23/2011 4:30 p.m.
Elizabeth Taylor made the hearts race for decades, but it was her own heart that failed in the end.
The 79-year-old actress died today from congestive heart failure, a condition that she fought for almost eight years.
Bovie Medical Corp. (NYSE:BVX) announced a flurry of personnel moves in its corner office and board room.
The company said current president and CEO Andrew Makrides will relinquish his title of president but keep his position as chief executive. J. Robert Saron, the firm’s chief sales and marketing officer, will assume the role of president. Saron formerly served as Bovie’s CEO from 1994 through 1998.
The best thing you can say about Angiotech Pharmaceutical Inc.’s (NSDQ:ANPI) fourth quarter is that it’s over.
In Japan, they’re dealing with a death toll sure to rise above 10,000, rolling blackouts and a nuclear disaster of as-yet-undetermined proportions. On Wall Street, investors in medical device makers are contending with issues of their own, as share prices slide and the long-term impact of the Japan earthquake remains unknown.
Boston Scientific Corp. (NYSE:BSX) is shedding more light on a top-down restructuring that has seen it re-align or replace more than 75 percent of its top 50 senior managers in the past year.
“We’ve spent a lot of time thinking about what the senior management team needs to be,” BSX CFO Jeff Capello said at the Barclay’s Capital 2011 Global Healthcare Conference. “The senior management team that’s rejuvenated is in place.”
Medtronic Inc. (NYSE:MDT) and Boston Scientific Corp. (NYSE:BSX) share a more than healthy rivalry when it comes to stents, pacemakers and other cardiovascular devices, but when it comes to basketball, it’s all Duke baby!
That’s because the Dukies literally infest the front offices and boardrooms of the two medical device giants.
These are tense times for the more than 13,000 employees of American medical device and diagnostic companies in Japan and their employers back stateside, as the country tries to recover from a devastating 8.9 magnitude earthquake and accompanying tsunami.
The impact of the quake will be felt far beyond the shores of the Pacific Ocean and into the heart of the medical device industry.
Boston Scientific Corp. (NYSE:BSX) co-founder John Abele will not stand for re-election to the company’s board when his current term expires in May. Two other long-time board members — Marye Anne Fox and Ray Groves — also plan to step down.
Boston Scientific Corp.’s (NYSE:BSX) third-generation stent platform, the platinum-chromium Omega bare-metal stent, won CE Mark approval in the European Union.
Boston Scientific said it plans to make the device available "immediately" in the EU and other countries that recognize the mark. It’s the first of a trio of stents the Natick, Mass.-based medical device maker plans to launch on the platform, according to a press release.
Boston Scientific Corp. (NYSE:BSX) completed its buyout of Plymouth, Minn.-based Atritech Inc.
Atritech’s CE Mark-approved Watchman device is designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke.
The $100 million cash deal, which was announced in January, could reach a value of $375 million with the addition of future milestone payments.